The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Zanubrutinib updates from ASH 2019
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, presents two updates on the BTK inhibitor zanubrutinib for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). This includes an update on a phase I/II study which showed high ORR and durable responses irrespective of 17p deletion (NCT02343120), and an update on Arm C of the SEQUOIA trial (NCT03336333), the largest prospective cohort of treatment-naive patients with 17p deletion. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
